Financial Impact of Psychedelic Medicine
Mental health issues, when left untreated, can be extremely costly. Those who are dealing with PTSD, anxiety, or similar disorders are more likely to:
Recent analysis revealed that organizations spend over $15,000 on average annually on each employee experiencing mental health issues (NSC).
Despite this investment, many employees may not respond to traditional treatment options such as antidepressants and therapy.
In spite of their widespread use, some studies have shown that 1/3 of patients don’t respond to antidepressants; others claim that these medications don’t have any significant impact on quality of life (BMC, 2019, PLOSONE, 2022).
Ketamine-assisted therapy (KAT), meanwhile, is helps “reshape” old thought patterns and fosters greater connections between brain cells.
In low doses, ketamine can support psychotherapy as it provides an opportunity for the temporary softening of psychological defenses, which may result in deeper self-reflection and psychotherapeutic processing.
Together, these components may help patients break long-standing, deeply ingrained thinking patterns associated with a variety of mental health conditions and, in turn, develop new ways of thinking and being. And it’s effective.
KAT is not simply covering up symptoms but instead, through its neuroplastic effects, is actually healing the root causes of mental health conditions.
One study on KAT found that 91% of participants showed improvements in generalized anxiety and 79% showed improvements in depression after treatment. Even those with treatment resistant depression have found that they feel better after one or two sessions.
Your employees need a form of treatment that goes farther than just covering up symptoms like a band-aid.
Psychedelic therapy has been shown to achieve often-dramatically better outcomes with depression, PTSD, substance use problems, and anxiety disorders.
This form of treatment does more than just cover up the symptoms and has a typically shorter course of treatment than pharmaceutical-based and psychotherapy-only interventions for mental health — all at a reduced cost compared to the usually long-term traditional interventions.
Despite Ketamine being FDA approved, on the list of WHO’s Essential Medicines, with over 50 years of demonstrated safety with humans and recent research showing KAT to be safe and effective, KAT in general is not an option for most of your employees due to its high out-of-pocket cost.
With standard health insurance coverage for KAT/PAT being years away, Enthea offers employers the ability to offer coverage for these treatments today.
Prioritizing employee mental health can also result in immense bottom-line benefits to the business as well including lower medical expenses, improved worker productivity, reduced absenteeism.
Enthea helps progressive organization provide psychedelic healthcare as a benefit on top of their existing health insurance. All Enthea plans are funded by the employer, with optional copays made by employees. We are building the nation’s largest provider network so that you can bring this innovative treatment to your employees.
The result isn’t just cost savings for them and for you — it demonstrates a commitment to their well-being and commitment to going above-and-beyond to support your team. With employee retention being a major focus for HR teams and organizations, this can go a long way to winning employee support.
To see the effects of psychedelic healthcare, read more about Dr. Bronner’s experience working with Enthea.